Item 5. Market for Registrant’s Common Equity
ITEM 5. MARKET FOR THE REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common sto ck is quoted on the New York Stock Exchange under the symbol “HAE.” As of March 28, 2026, we had 93 stockholders of record . We have not historically paid cash dividends and do not currently anticipate paying cash dividends in the future.
The following table provides information on the Company’s share repurchases during the fourth quarter of fiscal 2026:
Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program (1)(2)
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
(Dollars in Thousands, Except Per Share Data)
December 28, 2025 – January 24, 2026 131,937 $ 69.97 131,937 $ 415,768
January 25, 2026 – February 21, 2026 228,520 $ 69.00 228,520 $ 400,000
February 22, 2026 – March 28, 2026 1,218,798 $ 61.54 1,218,798 $ 325,000
Total 1,579,255 1,579,255
__________
(1) In April 2025, our Board approved a three-year share repurchase program authorizing the repurchase of up to $500.0 million of Haemonetics common stock, based on market conditions, through April 2028. Under the 2025 share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions.
(2) During the fourth quarter of fiscal 2026, we repurchased $25.0 million of our common stock pursuant to a previously executed Rule 10b5-1 trading plan. The total number of shares repurchased pursuant to the Rule 10b5-1 trading plan was 360,457 at an average price per share upon final settlement of $69.36. In March 2026, we completed a $75.0 million repurchase of our common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Goldman Sachs & Co. (“Goldman Sachs”) in February 2026. The total number of shares repurchased under the ASR was 1,218,798 at an average price per share upon final settlement of $61.54. As of March 28, 2026, the total remaining authorization for repurchases of our common stock under the share repurchase program was $325.0 million.
ITEM 6. RESERVED
35
Table of Contents
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.